Literature DB >> 26601715

Banff study of pathologic changes in lung allograft biopsy specimens with donor-specific antibodies.

William Dean Wallace1, Ning Li2, Claus B Andersen3, A Valeria Arrossi4, Medhat Askar4, Gerry J Berry5, Matthew M DeNicola6, Desley A Neil7, Elizabeth N Pavlisko8, Elaine F Reed6, Myriam Remmelink9, S Sam Weigt10, Birgit Weynand11, Jennifer Q Zhang6, Marie M Budev12, Carol F Farver4.   

Abstract

BACKGROUND: The diagnosis of antibody-mediated rejection (AMR) in the lung transplant is still an area under investigation. We performed a blinded multicenter study to determine if any statistically significant histologic findings in transbronchial biopsy specimens from lung transplant patients correlate with the presence of donor-specific antibodies (DSAs).
METHODS: We asked 9 pathologists with experience in lung transplantation to evaluate 161 lung transplant biopsy specimens for various histologic parameters. The findings were correlated with antibody status positive for DSAs, positive for non-DSAs, and no antibodies (NABs) present. The significance of each histologic variable was reviewed.
RESULTS: We found no statistically significant association with acute cellular rejection, airway inflammation, or bronchiolitis obliterans and the presence or absence of antibodies. However, biopsy specimens with DSAs had a statistically significant difference vs NABs in the setting of acute lung injury, with or without diffuse alveolar damage (p = 0.0008), in the presence of capillary neutrophilic inflammation (p = 0.0014), and in samples with endotheliitis (p = 0.0155). In samples with complement 4d staining, there was a trend but no statistically significant difference between specimens associated with DSAs and specimens with NABs.
CONCLUSIONS: Capillary inflammation, acute lung injury, and endotheliitis significantly correlated with DSAs. The infrequently observed diffuse staining for complement 4d limits the usefulness of this stain.
Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute lung injury; antibody-mediated rejection; biopsy specimen; capillary inflammation; donor-specific antibodies; endotheliitis; lung transplant

Mesh:

Substances:

Year:  2015        PMID: 26601715     DOI: 10.1016/j.healun.2015.08.021

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  11 in total

Review 1.  Acute rejection.

Authors:  Mark Benzimra; Greg L Calligaro; Allan R Glanville
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

2.  Endothelial Cell-Derived Interleukin-18 Released During Ischemia Reperfusion Injury Selectively Expands T Peripheral Helper Cells to Promote Alloantibody Production.

Authors:  Lufang Liu; Caodi Fang; Whitney Fu; Bo Jiang; Guangxin Li; Lingfeng Qin; Jacob Rosenbluth; Gavin Gong; Catherine B Xie; Peter Yoo; George Tellides; Jordan S Pober; Dan Jane-Wit
Journal:  Circulation       Date:  2019-11-20       Impact factor: 29.690

Review 3.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

Review 4.  Extracellular Vesicles Mediate Immune Responses to Tissue-Associated Self-Antigens: Role in Solid Organ Transplantations.

Authors:  Ranjithkumar Ravichandran; Sandhya Bansal; Mohammad Rahman; Angara Sureshbabu; Narendra Sankpal; Timothy Fleming; Ankit Bharat; Thalachallour Mohanakumar
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

5.  Non-Human Leukocyte Antigen Antibody-Mediated Lung Transplant Rejection: The Other Anti-A.

Authors:  Anthony D Vinson; Reinaldo Rampolla-Selles; E Shannon Cooper; Caroline R Alquist
Journal:  Ochsner J       Date:  2018

6.  Gene Expression Profiling of Bronchoalveolar Lavage Cells Preceding a Clinical Diagnosis of Chronic Lung Allograft Dysfunction.

Authors:  S Samuel Weigt; Xiaoyan Wang; Vyacheslav Palchevskiy; Aric L Gregson; Naman Patel; Ariss DerHovanessian; Michael Y Shino; David M Sayah; Shirin Birjandi; Joseph P Lynch; Rajan Saggar; Abbas Ardehali; David J Ross; Scott M Palmer; David Elashoff; John A Belperio
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

7.  FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.

Authors:  Pascale Paul; Pascal Pedini; Luc Lyonnet; Julie Di Cristofaro; Anderson Loundou; Mathieu Pelardy; Agnes Basire; Françoise Dignat-George; Jacques Chiaroni; Pascal Thomas; Martine Reynaud-Gaubert; Christophe Picard
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

8.  Usefulness of gene expression profiling of bronchoalveolar lavage cells in acute lung allograft rejection.

Authors:  S Samuel Weigt; Xiaoyan Wang; Vyacheslav Palchevskiy; Xinmin Li; Naman Patel; David J Ross; John Reynolds; Pali D Shah; Lara A Danziger-Isakov; Stuart C Sweet; Lianne G Singer; Marie Budev; Scott Palmer; John A Belperio
Journal:  J Heart Lung Transplant       Date:  2019-05-07       Impact factor: 10.247

9.  Possible Involvement of Central Nervous System in COVID-19 and Sequence Variability of SARS-CoV-2 Revealed in Autopsy Tissue Samples: A Case Report.

Authors:  Lis Høy Marbjerg; Christina Jacobsen; Jannik Fonager; Claus Bøgelund; Morten Rasmussen; Anders Fomsgaard; Jytte Banner; Veronika Vorobieva Solholm Jensen
Journal:  Clin Pathol       Date:  2021-03-27

10.  Machine learning-based analysis of alveolar and vascular injury in SARS-CoV-2 acute respiratory failure.

Authors:  Fiorella Calabrese; Federica Pezzuto; Francesco Fortarezza; Annalisa Boscolo; Francesca Lunardi; Chiara Giraudo; Annamaria Cattelan; Claudia Del Vecchio; Giulia Lorenzoni; Luca Vedovelli; Nicolò Sella; Marco Rossato; Federico Rea; Roberto Vettor; Mario Plebani; Emanuele Cozzi; Andrea Crisanti; Paolo Navalesi; Dario Gregori
Journal:  J Pathol       Date:  2021-03-30       Impact factor: 9.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.